Abbott Laboratories (ABT) Stock Forecast & Price Target
ABT Analyst Ratings
Strong Buy
17Buy2Hold0Sell
Based on 19 analysts giving stock ratings to Abbott Laboratories in the past 3 months
ABT Stock 12 Month Forecast
Average Price Target
MXN 2,290.81â–²(14.83% Upside)Based on 19 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is MXN 2,290.81 with a high forecast of MXN 2,536.21 and a low forecast of MXN 2,160.48. The average price target represents a 14.83% change from the last price of MXN 1,995.00.
Past 12 Months12 Month ForecastDec2025Sep2026
HighMXN 2.54K
AverageMXN 2.29K
LowMXN 2.16K
Highest Price TargetHighestMXN 2,536.21Average Price TargetMXN 2,290.81Lowest Price TargetLowestMXN 2,160.48
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Travis Steed | Bank of America Securities | MXN 2,160.48 | buy | 8.29%Upside | Reiterated | 10/30/26 | ||
| David Toung | Argus Research | ― | hold | ― | Downgraded | 10/26/26 | ||
| Larry Biegelsen | Wells Fargo | MXN 2,235.62→MXN 2,254.41 | buy | 13.00%Upside | Reiterated | 10/23/26 | ||
| Vijay Kumar | Evercore ISI | MXN 2,329.56→MXN 2,254.41 | buy | 13.00%Upside | Reiterated | 10/23/26 | ||
| Joanne Wuensch | Citi | MXN 2,348.34→MXN 2,291.98 | buy | 14.89%Upside | Assigned | 10/22/26 | ||
| Christopher Pasquale | Barclays | MXN 2,254.41 | buy | 13.00%Upside | Reiterated | 10/22/26 | ||
| David Rescott | Robert W. Baird | MXN 2,273.20→MXN 2,310.77 | buy | 15.83%Upside | Reiterated | 10/22/26 | ||
| Adam Maeder | Piper Sandler | MXN 2,216.84 | buy | 11.12%Upside | Reiterated | 10/22/26 | ||
| Josh Jennings | TD Cowen | MXN 2,536.21→MXN 2,216.84 | buy | 11.12%Upside | Assigned | 10/22/26 | ||
 Unknown AnalystNot Ranked | Oppenheimer | MXN 2,160.48 | buy | 8.29%Upside | Reiterated | 10/22/26 | ||
| Rick Wise | Stifel Nicolaus | MXN 2,254.41 | buy | 13.00%Upside | Reiterated | 10/22/26 | ||
| Robbie Marcus | J.P. Morgan | MXN 2,254.41→MXN 2,216.84 | buy | 11.12%Upside | Reiterated | 10/22/26 | ||
| Marie Thibault | BTIG | MXN 2,517.42→MXN 2,348.34 | buy | 17.71%Upside | Reiterated | 10/21/26 | ||
| Kendall Au | RBC Capital | MXN 2,442.28→MXN 2,348.34 | buy | 17.71%Upside | Assigned | 10/21/26 | ||
| Unknown AnalystNot Ranked | Leerink Partners | ― | hold | ― | Reiterated | 10/12/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Travis Steed | 10/30/26 | MXN 2,160.48 | buy | 8.29%Upside | Reiterated | Bank of America Securities | ||
| David Toung | 10/26/26 | ― | hold | ― | Downgraded | Argus Research | ||
| Larry Biegelsen | 10/23/26 | MXN 2,235.62→MXN 2,254.41 | buy | 13.00%Upside | Reiterated | Wells Fargo | ||
| Vijay Kumar | 10/23/26 | MXN 2,329.56→MXN 2,254.41 | buy | 13.00%Upside | Reiterated | Evercore ISI | ||
| Joanne Wuensch | 10/22/26 | MXN 2,348.34→MXN 2,291.98 | buy | 14.89%Upside | Assigned | Citi | ||
| Christopher Pasquale | 10/22/26 | MXN 2,254.41 | buy | 13.00%Upside | Reiterated | Barclays | ||
| David Rescott | 10/22/26 | MXN 2,273.20→MXN 2,310.77 | buy | 15.83%Upside | Reiterated | Robert W. Baird | ||
| Adam Maeder | 10/22/26 | MXN 2,216.84 | buy | 11.12%Upside | Reiterated | Piper Sandler | ||
| Josh Jennings | 10/22/26 | MXN 2,536.21→MXN 2,216.84 | buy | 11.12%Upside | Assigned | TD Cowen | ||
| Unknown AnalystNot Ranked | 10/22/26 | MXN 2,160.48 | buy | 8.29%Upside | Reiterated | Oppenheimer | ||
| Rick Wise | 10/22/26 | MXN 2,254.41 | buy | 13.00%Upside | Reiterated | Stifel Nicolaus | ||
| Robbie Marcus | 10/22/26 | MXN 2,254.41→MXN 2,216.84 | buy | 11.12%Upside | Reiterated | J.P. Morgan | ||
| Marie Thibault | 10/21/26 | MXN 2,517.42→MXN 2,348.34 | buy | 17.71%Upside | Reiterated | BTIG | ||
| Kendall Au | 10/21/26 | MXN 2,442.28→MXN 2,348.34 | buy | 17.71%Upside | Assigned | RBC Capital | ||
| Unknown AnalystNot Ranked | 10/12/26 | ― | hold | ― | Reiterated | Leerink Partners |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Abbott Laboratories
3 Months
Success Rate17/23 ratings generated profit
74%
Average Return
+2.97%
Copying Matthew Taylor's trades and holding each position for 3 Months would result in 73.91% of your transactions generating a profit, with an average return of +2.97% per trade.
1 Year
Success Rate34/43 ratings generated profit
79%
Average Return
+14.84%
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 79.07% of your transactions generating a profit, with an average return of +14.84% per trade.
2 Years
Success Rate17/23 ratings generated profit
74%
Average Return
+27.59%
Copying Matthew Taylor's trades and holding each position for 2 Years would result in 73.91% of your transactions generating a profit, with an average return of +27.59% per trade.
ABT Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 38 | 33 | 42 | 36 | 39 |
| Hold | 5 | 0 | 0 | 0 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 43 | 33 | 42 | 36 | 41 |
In the current month, ABT has received 39 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ABT average Analyst price target in the past 3 months is 2,290.81.
ABT Financial Forecast
HighMXN 30.73
ConsensusMXN 30.63
LowMXN 30.48
ABT Earnings Forecast
Next quarter’s earnings estimate for ABT is MXN 30.63 with a range of MXN 30.48 to MXN 30.73. The previous quarter’s EPS was MXN 26.56. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighMXN 251B
ConsensusMXN 247B
LowMXN 246B
ABT Sales Forecast
Next quarter’s sales forecast for ABT is MXN 247.20B with a range of MXN 245.78B to MXN 251.30B. The previous quarter’s sales results were MXN 243.37B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
ABT Stock Forecast FAQ
What is MX:ABT’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbott Laboratories’s 12-month average price target is Mex$2,290.81.
What is MX:ABT’s upside potential, based on the analysts’ average price target?
Abbott Laboratories has 14.83% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Abbott Laboratories a Buy, Sell or Hold?
Abbott Laboratories has a consensus rating of Strong Buy, which is based on 17 buy ratings, 2 hold ratings and 0 sell ratings.
What is Abbott Laboratories’s share price target?
The average share price target for Abbott Laboratories is Mex$2,290.81. This is based on 19 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$2,536.21, and the lowest forecast is Mex$2,160.48. The average share price target represents a 14.83% increase from the current price of Mex$1,995.
What do analysts say about Abbott Laboratories?
Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Street analysts.
How can I buy shares of Abbott Laboratories?
To buy shares of MX:ABT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.